{"product_id":"zimberelimab","title":"Zimberelimab","description":"\u003cp\u003eZimberelimab  is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lung cancer and classical Hodgkin's lymphoma. Based on the results of a phase II trial, zimberelimab was recently approved for marketing in China as treatment for relapsed or refractory classical Hodgkin's lymphoma. \u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eZimberelimab \u003c\/span\u003esold under the brand name 誉妥® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eOn July 4, 2023, Zimberelimab was approved by NMPA for the treatment of recurrent or metastatic cervical cancer with positive PD-L1 expression (CPS ≥ 1) that has progressed after one or more lines of standard platinum-containing chemotherapy.\u003c\/p\u003e","brand":"Gloria Biosciences Co. Ltd., China","offers":[{"title":"Default Title","offer_id":44797956423723,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-2545.png?v=1787022260","url":"https:\/\/xomeds.com\/products\/zimberelimab","provider":"XOMEDS","version":"1.0","type":"link"}